Myelin matters: Proteomic insights into white matter disorders

Expert Review of Proteomics

Volumn 7, Issue 2, 2010, Pages 159-164

  Werner, Hauke B ^a   Jahn, Olaf ^a,b  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b Deutsche Forschungsgemeinschaft   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; HIRUDIN; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; BRAIN DEVELOPMENT; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM; EDITORIAL; HUMAN; LEUKODYSTROPHY; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEOMICS; WHITE MATTER;

ANIMALS; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS; MODELS, BIOLOGICAL; MYELIN SHEATH; NERVE FIBERS, MYELINATED; PROTEOMICS;

EID: 77950811709     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.105     Document Type: Editorial

References (73)

1. Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu. Rev. Neurosci. 31, 535-561 (2008).
2. Nguyen T, Mehta NR, Conant K et al. Axonal protective effects of the myelin-associated glycoprotein. J. Neurosci. 29(3), 630-637 (2009).
3. Poliak S, Peles E. The local differentiation of myelinated axons at nodes of Ranvier. Nat. Rev. Neurosci. 4(12), 968-980 (2003). (Pubitemid 37486673)
4. Hildebrand C, Remahl S, Persson H, Bjartmar C. Myelinated nerve fibres in the CNS. Prog. Neurobiol. 40(3), 319-384 (1993). (Pubitemid 23017425)
5. Sherman DL, Brophy PJ. Mechanisms of axon ensheathment and myelin growth. Nat. Rev. Neurosci. 6(9), 683-690 (2005).
6. Simons M, Trotter J. Wrapping it up: the cell biology of myelination. Curr. Opin. Neurobiol. 17(5), 533-540 (2007).
7. Boespflug-Tanguy O, Labauge P, Fogli A, Vaurs-Barriere C. Genes involved in leukodystrophies: a glance at glial functions. Curr. Neurol. Neurosci. Rep. 8(3), 217-229 (2008).
8. Lyon G, A. Fattal-Valevski, Kolodny EH. Leukodystrophies: clinical and genetic aspects. Top. Magn. Reson. Imaging 17(4), 219-242 (2006). (Pubitemid 46594174)
9. Phelan JA, Lowe LH, Glasier CM. Pediatric neurodegenerative white matter processes: leukodystrophies and beyond. Pediatr. Radiol. 38(7), 729-749 (2008).
10. Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 72(8), 750-759 (2009).
11. Garbern JY. Pelizaeus-Merzbacher disease: genetic and cellular pathogenesis. Cell. Mol. Life Sci. 64(1), 50-65 (2007). (Pubitemid 46159445)
12. Saugier-Veber P, Munnich A, Bonneau D et al. X-linked spastic paraplegia and Pelizaeus-Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat. Genet. 6(3), 257-262 (1994). (Pubitemid 24188622)
13. Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin. Microbiol. Rev. 22(1), 99-126 (2009).
14. Henneke M, Diekmann S, Ohlenbusch A et al. RNASET2-deficient cystic leukoencephalopathy resembles congenital cytomegalovirus brain infection. Nat. Genet. 41(7), 773-775 (2009).
15. Holmoy T, Harbo H, Vartdal F, Spurkland A. Genetic and molecular approaches to the immunopathogenesis of multiple sclerosis: an update. Curr. Mol. Med. 9(5), 591-611 (2009).
16. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 17(2), 210-218 (2007). (Pubitemid 46466140)
17. Veldhoen M, Hirota K, Westendorf AM et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453(7191), 106-109 (2008). (Pubitemid 351630329)
18. Fugger L, Friese MA, Bell JI. From genes to function: the next challenge to understanding multiple sclerosis. Nat. Rev. Immunol. 9(6), 408-417 (2009).
19. Korn T. Pathophysiology of multiple sclerosis. J. Neurol. 255(Suppl. 6), 2-6 (2008).
20. Satoh JI, Tabunoki H, Yamamura T. Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. Mult. Scler. 15(5), 531-541 (2009).
21. Dendrou CA, Plagnol V, Fung E et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat. Genet. 41(9), 1011-1015 (2009).
22. Hafler DA, Compston A, Sawcer S et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357(9), 851-862 (2007). (Pubitemid 47347319)
23. Norton, WT, Poduslo SE. Myelination in rat brain: method of myelin isolation. J. Neurochem. 21(4), 749-757 (1973).
24. Roth AD, Ivanova A, Colman DR. New observations on the compact myelin proteome. Neuron Glia Biol. 2(1), 15-21 (2006). (Pubitemid 43248060)
25. Taylor CM, Marta CB, Claycomb RJ et al. Proteomic mapping provides powerful insights into functional myelin biology. Proc. Natl Acad. Sci. USA 101(13), 4643-4648 (2004).
26. Vanrobaeys F, Van Coster R, Dhondt G, Devreese B, Van Beeumen J. Profiling of myelin proteins by 2D-gel electrophoresis and multidimensional liquid chromatography coupled to MALDI TOF-TOF mass spectrometry. J. Proteome Res. 4(6), 2283-2293 (2005). (Pubitemid 41814298)
27. Werner HB, Kuhlmann K, Shen S et al. Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J. Neurosci. 27(29), 7717-7730 (2007). (Pubitemid 47093807)
28. Huang JK, Phillips GR, Roth AD et al. Glial membranes at the node of Ranvier prevent neurite outgrowth. Science 310(5755), 1813-1817 (2005).
29. Baer AS, Syed YA, Kang SU et al. Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. Brain 132(Pt 2), 465-481 (2009).
30. Jahn O, Tenzer S, Werner HB. Myelin proteomics: molecular anatomy of an insulating sheath. Mol. Neurobiol. 40(1), 55-72 (2009).
31. Filbin MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat. Rev. Neurosci. 4(9), 703-713 (2003). (Pubitemid 37280150)
32. Buser AM, Erne B, Werner HB, Nave KA, Schaeren-Wiemers N. The septin cytoskeleton in myelinating glia. Mol. Cell. Neurosci. 40(2), 156-166 (2009).
33. Ishii A, Dutta R, Wark GM et al. Human myelin proteome and comparative analysis with mouse myelin. Proc. Natl Acad. Sci. USA 106(34), 14605-14610 (2009).
34. Mobius W, Patzig J, Nave KA, Werner HB. Phylogeny of proteolipid proteins: divergence, constraints, and the evolution of novel functions in myelination and neuroprotection. Neuron Glia Biol. 4(2), 111-127 (2008).
35. Waehneldt TV. Phylogeny of myelin proteins. Ann. NY Acad. Sci. 605, 15-28 (1990).
36. Yang JW, Suder P, Silberring J, Lubec G. Proteome analysis of mouse primary astrocytes. Neurochem. Int. 47(3), 159-172 (2005). (Pubitemid 40848678)
37. Dumont D, Noben JP, Moreels M et al. Characterization of mature rat oligodendrocytes: a proteomic approach. J. Neurochem. 102(2), 562-576 (2007). (Pubitemid 47000599)
38. Gupta N, Wollscheid B, Watts JD, Scheer B, Aebersold R, DeFranco AL. Quantitative proteomic analysis of B cell lipid rafts reveals that ezrin regulates antigen receptor-mediated lipid raft dynamics. Nat. Immunol. 7(6), 625-633 (2006). (Pubitemid 43797344)
39. Elkabes S, Li H. Proteomic strategies in multiple sclerosis and its animal models. Proteomics Clin. Appl. 1(11), 1393-1405 (2007).
40. Tumani H, Hartung HP, Hemmer B et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 35(2), 117-127 (2009).
41. Cayrol R, Wosik K, Berard JL et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat. Immunol. 9(2), 137-145 (2008).
42. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129(Pt 8), 1953-1971 (2006). (Pubitemid 44289062)
43. Krishnamoorthy G, Saxena A, Mars LT et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat. Med. 15(6), 626-632 (2009).
44. Raine CS, Cannella B, Hauser SL, Genain CP. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol. 46(2), 144-160 (1999). (Pubitemid 29382870)
45. Reindl M, Linington C, Brehm U et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 122(Pt 11), 2047-2056 (1999).
46. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2́,3́-cyclic nucleotide 3́-phosphodiesterase in the CNS of adult rats. J. Neurochem. 52(1), 296-304 (1989). (Pubitemid 19023382)
47. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J. Neurochem. 72(1), 1-9 (1999).
48. Delarasse C, Daubas P, Mars LT et al. Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J. Clin. Invest. 112(4), 544-553 (2003). (Pubitemid 38056339)
49. Marta CB, Montano MB, Taylor CM, Taylor AL, Bansal R, Pfeiffer SE. Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis. J. Biol. Chem. 280(10), 8985-8993 (2005). (Pubitemid 40409590)
50. Krishnamoorthy G, Wekerle H. EAE: an immunologist's magic eye. Eur. J. Immunol. 39(8), 2031-2035 (2009).
51. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. 31, 247-269 (2008).
52. Kaushansky N, Eisenstein M, Zilkha- Falb R, Ben-Nun A. The myelin-associated oligodendrocytic basic protein (MOBP) as a relevant primary target autoantigen in multiple sclerosis. Autoimmun. Rev. 9(4), 233-236 (2009).
53. Dornmair K, Meinl E, Hohlfeld R. Novel approaches for identifying target antigens of autoreactive human B and T cells. Semin. Immunopathol. 31(4), 467-477 (2009).
54. Kanter JL, Narayana S, Ho PP et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12(1), 138-143 (2006). (Pubitemid 43050089)
55. Quintana FJ, Farez MF, Viglietta V et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc. Natl Acad. Sci. USA 105(48), 18889-18894 (2008).
56. Robinson WH, DiGennaro C, Hueber W et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat. Med. 8(3), 295-301 (2002). (Pubitemid 34250109)
57. Robinson WH, Fontoura P, Lee BJ et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol. 21(9), 1033-1039 (2003). (Pubitemid 37064732)
58. Chabas D, Baranzini SE, Mitchell D et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294(5547), 1731-1735 (2001).
59. Ousman SS, Tomooka BH, van Noort JM et al. Protective and therapeutic role for aB-crystallin in autoimmune demyelination. Nature 448(7152), 474-479 (2007).
60. Ransohoff RM. Inflammatory disease: assault on the guardian. Nature 448(7152), 421-422 (2007).
61. Mathey EK, Derfuss T, Storch MK et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 204(10), 2363-2372 (2007). (Pubitemid 47529322)
62. Derfuss T, Parikh K, Velhin S et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc. Natl Acad. Sci. USA 106(20), 8302-8307 (2009).
63. Howell OW, Palser A, Polito A et al. Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain 129(Pt 12), 3173-3185 (2006). (Pubitemid 44871434)
64. Labasque M, Faivre-Sarrailh C. GPI-anchored proteins at the node of Ranvier. FEBS Lett. DOI:10.1016/j. febslet.2009.08.025 (2009) (Epub ahead of print).
65. Zonta B, Tait S, Melrose S et al. Glial and neuronal isoforms of neurofascin have distinct roles in the assembly of nodes of Ranvier in the central nervous system. J. Cell. Biol. 181(7), 1169-1177 (2008). (Pubitemid 351915490)
66. Harauz G, Ladizhansky V, Boggs JM. Structural polymorphism and multifunctionality of myelin basic protein. Biochemistry 48(34), 8094-8104 (2009).
67. Kim JK, Mastronardi FG, Wood DD, Lubman DM, Zand R, Moscarello MA. Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol. Cell. Proteomics 2(7), 453-462 (2003).
68. Han MH, Hwang SI, Roy DB et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451(7182), 1076-1081 (2008).
69. Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann. Neurol. 62(4), 314-326 (2007). (Pubitemid 350105946)
70. Cahoy JD, Emery B, Kaushal A et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 28(1), 264-278 (2008).
71. Dugas JC, Tai YC, Speed TP, Ngai J, Barres BA. Functional genomic analysis of oligodendrocyte differentiation. J. Neurosci. 26(43), 10967-10983 (2006). (Pubitemid 44772187)
72. Lin G, Mela A, Guilfoyle EM, Goldman JE. Neonatal and adult O4(+) oligodendrocyte lineage cells display different growth factor responses and different gene expression patterns. J. Neurosci. Res. 87(15), 3390-3402 (2009).
73. Nielsen JA, Maric D, Lau P, Barker JL, Hudson LD. Identification of a novel oligodendrocyte cell adhesion protein using gene expression profiling. J. Neurosci. 26(39), 9881-9891 (2006). (Pubitemid 44477150)